text: Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors - Full Text View - ClinicalTrials.gov
  ClinicalTrials.gov Identifier: NCT00884676
  Unspecified Adult Solid Tumor, Protocol Specific Drug: Ixabepilone Drug: Sunitinib Phase 1
  Drug Information available for: Ixabepilone Sunitinib malate Sunitinib
  Safety and toxicity profile as assessed by NCI CTCAE version 3.0 [ Time Frame: Approximately 18-30 months ]
  Recommended Phase II dose of Ixabepilone when administered with Sunitinib [ Time Frame: Schedule A (12 - 18 months); Schedule B (6 -12 months after Schedule A) ]
  Pharmacokinetic profiles of Ixabepilone and Sunitinib malate and correlation with activity and/or toxicity [ Time Frame: Approximately 18-30 months ]
  Efficacy data (complete response, partial response, or stable disease) of these treatment combinations [ Time Frame: Approximately 18-30 months ]
  Correlation of changes in angiogenesis biomarkers with clinical (safety and efficacy) and pharmacokinetic parameters [ Time Frame: Approximately 18-30 months ]